Business Wire

Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe

11.8.2026 13:30:00 CEST | Business Wire | Press release

Share

Transaction highlights Advances Alfasigma’s M&A-led global growth strategy, purposely focused on immunology and gastroenterology. Synergy with Alfasigma’s specialty rheumatology portfolio, adding Nordic Pharma’s rheumatoid arthritis business, including the Nordimet® franchise. Expands footprint by adding Canada and Japan; strengthens presence in Europe, with direct operations in 18 countries, with 265 employees. Adds approximately €190 million in 2025 revenue. Financial terms of the transaction are not disclosed.

Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, today announced that it has entered into a share purchase agreement with SEVER Life Sciences B.V. ("SEVER") for the sale of 100% of the shares of Nordic Group B.V. (“Nordic Pharma”) and its subsidiaries, a privately owned specialty pharmaceutical company with direct operations in Europe, Canada and Japan.

The acquisition will add Nordic Pharma’s established rheumatoid arthritis business, led by the Nordimet® methotrexate franchise, to Alfasigma’s rheumatology portfolio, which includes the Jyseleca® franchise. It will also deepen Alfasigma’s commercial reach through direct operations in 18 countries across Europe and add commercial platforms in Canada and Japan. In addition to rheumatology, the acquisition includes Nordic Pharma’s portfolio in women’s health, critical care and ophthalmology. It also brings 265 employees with specialist capabilities and expertise.

The transaction is subject to customary closing conditions, including any requiredregulatory agency clearances.

The transaction supports Alfasigma’s M&A-led growth strategy as it actively expands its international specialty and rare business, with a focus on gastroenterology and immunology. It follows recent portfolio-building initiatives, including the acquisition of Jyseleca® in inflammatory diseases and the licensing agreement with GSK for linerixibat for the treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patients.

Francesco Balestrieri, Chief Executive Officer, Alfasigma, said:

“Alfasigma is pursuing a deliberate strategy to identify the right opportunities to build our global specialty and rare disease business, focused on areas of significant unmet need in gastroenterology and immunology. The acquisition of Nordic Pharma marks a decisive step forward in that journey, strengthening our European presence and expanding our rheumatology portfolio. By combining our portfolios, scientific expertise and talented teams, we are better positioned to deliver meaningful innovation and value for patients and shareholders.”

Charlotte Phelps, Chief Executive Officer, Nordic Group B.V., commented:

“Alfasigma is the right partner for Nordic Pharma as we enter our next phase of growth. Both companies are patient-focused, rooted in science and entrepreneurial. We look forward to combining our experience to support patients.”

Forward looking statements

This press release contains forward‑looking statements. Actual results may differ materially due to various risks and uncertainties, including regulatory outcomes and market conditions.

About Alfasigma

Alfasigma is a privately owned, medium-sized, global pharmaceutical company, headquartered in Italy with offices in Bologna and Milan. Its products are distributed in more than 100 markets worldwide. The company employs approximately 4,000 people. Alfasigma continues to expand its international presence and portfolio through acquisitions, partnerships, and licensing agreements. Its portfolio ranges from consumer healthcare products and primary care treatments to specialty and rare disease medications, with key therapeutic focus on gastroenterology, immunology, and vascular health. Visit www.alfasigma.com.

About Jyseleca® (filgotinib)

Approved for use as a second-line treatment in inflammatory and autoimmune diseases including rheumatoid arthritis and ulcerative colitis. Jyseleca is marketed by Alfasigma in EU and EEA countries and in the UK.

About SEVER Life Sciences B.V.

SEVER Life Sciences B.V. is an international life sciences group with activities spanning pharmaceutical development, manufacturing and specialty pharmaceuticals. Following completion, SEVER will continue to focus on the development of its remaining businesses, namely Sever Pharma Solutions AB, Farmaprim S.R.L., Esperante Development B.V. and Nordic Pharma Inc.

About Nordic Group B.V.

Nordic Group B.V. is an international specialty pharmaceutical company headquartered in Hoofddorp, The Netherlands, with a diversified portfolio of branded and niche pharmaceutical products marketed across Europe and selected international markets. Visit www.nordicpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260804708645/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Spatial Announces Release 2027 1.0 with New Enhancements Across CAD Modeling, Interoperability, Data Preparation, and Meshing17.11.2026 20:10:00 CET | Press release

Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced the availability of its 2027 1.0 Release. This latest release introduces new capabilities and enhancements across Spatial's 3D ACIS Modeler, CGM Modeler, 3D InterOp, Data Prep and CSM/CVM product lines. Designed to improve efficiency, flexibility and robustness across CAD modeling, interoperability, data preparation and simulation workflows, the release delivers enhanced geometry processing, expanded modeling capabilities, improved CAD translation and advances in mesh generation for a better workflow coverage. 3D ACIS Modeler Enhanced Blending (Filleting) The 3D ACIS Modeler introduces support for asymmetric fixed-width blends with a conic cross-section, providing users with finer control over smooth transitions between edges. This enhancement builds on the symmetric fixed-width blend with a conic cross-section capabilit

Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption17.11.2026 19:00:00 CET | Press release

Myths and misconceptions about electric cars, from battery lifespan and fire risk to grid collapse, are the biggest barrier to EV adoption, according to respondents to the annual Global EV Driver Survey. The 2026 survey draws on responses from more than 29,500 EV drivers across 34 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117539716/en/ MYTHS. Battery lifespan (72%), fire risk (58%) and grid collapse (45%) top the list of EV myths reported by respondents to the 2026 Global EV Driver Survey, which gathered responses from more than 29,500 EV drivers across 34 countries. “The EV transition is not just an infrastructure or affordability challenge. It is also an information challenge. Outdated information and misconceptions continue to influence decisions long after the technology has moved on,” says Ellen Hiep, from the Steering Committee of the Global EV Alliance (GEVA). Myths the greatest barrier Asked to ide

TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 18:04:00 CET | Press release

Seasoned biotech CFO with gene therapy, diagnostics, IPO and Wall Street experience joins the executive leadership team TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and

Visa Report: AI-Enabled Fraud and Third-Party Attacks Are Scaling Worldwide17.11.2026 16:40:00 CET | Press release

Third-party incidents surged 62%, while Visa Scam Disruption identified more than $1.4 billion in potential fraud Fraud is becoming more automated, targeted and global as criminals use AI to exploit weak points across the payments ecosystem and target third-party providers that can provide access to multiple downstream payment organizations, according to the Visa (NYSE: V) Fall 2026 Biannual Threats Report released today during International Fraud Awareness Week. Developed by Visa Payment Ecosystem Risk and Control (PERC), the report examines threat activity observed between January and June 2026 and finds that AI is not creating entirely new categories of fraud. Instead, it is helping criminals that execute existing attacks faster, at greater scale, and with greater precision, while increasingly targeting third-party providers that can provide access to multiple downstream organizations at once. Although attack volumes increased in several areas, the report also found evidence that co

Sparxity Appoints former Cray CEO Peter Ungaro and Semiconductor Veteran Daniel Armbrust to its Advisory Board17.11.2026 16:00:00 CET | Press release

Appointments bring decades of leadership experience in supercomputing, semiconductor commercialization, and scaling advanced computing business Sparxity, a leader in sparse-native computing, today announced that Peter Ungaro, former President and CEO of Cray, Inc., and Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst, have joined its Advisory Board as independent members. Armbrust has been elected Chairman of the Advisory Board and Ungaro Deputy Chairman by their fellow board members. The appointments strengthen the company’s leadership as it scales its sparse-native computing technology for next-generation AI and high-performance computing (HPC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117761685/en/ From left to right, Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst and Peter Ungaro, former President and CEO of Cray, Inc. Peter Ungaro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye